Cargando…

Identification of ERBB Pathway-Activated Cells in Triple-Negative Breast Cancer

Intratumor heterogeneity within a single tumor mass is one of the hallmarks of malignancy and has been reported in various tumor types. The molecular characterization of intratumor heterogeneity in breast cancer is a significant challenge for effective treatment. Using single-cell RNA sequencing (RN...

Descripción completa

Detalles Bibliográficos
Autor principal:	Cho, Soo Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korea Genome Organization 2019
Materias:	Clinical Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459170/ https://www.ncbi.nlm.nih.gov/pubmed/30929404 http://dx.doi.org/10.5808/GI.2019.17.1.e3

Ejemplares similares

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells
por: Miano, Carmen, et al.
Publicado: (2022)

Phosphorylation of the ErbB3 binding protein Ebp1 by p21-activated kinase 1 in breast cancer cells
por: Akinmade, D, et al.
Publicado: (2008)

Nuclear ErbB-2-Induced Transcriptome Drives Triple Negative Breast Cancer Growth
por: Chervo, Maria F, et al.
Publicado: (2021)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer
por: Benusiglio, P R, et al.
Publicado: (2006)

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
por: Robertson, L, et al.
Publicado: (2012)

Androgen Receptor Highjacks ErbB-2 Nuclear Function to Induce Triple Negative Breast Cancer Growth
por: Deamicis, Agustina Roldán, et al.
Publicado: (2021)

LncRNA Uc003xsl.1-Mediated Activation of the NFκB/IL8 Axis Promotes Progression of Triple-Negative Breast Cancer
por: Xu, Ying, et al.
Publicado: (2022)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

The hedgehog pathway in triple‐negative breast cancer
por: Habib, Joyce G., et al.
Publicado: (2016)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis
por: Dong, Pengzhi, et al.
Publicado: (2018)

Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis
por: Li, Liqi, et al.
Publicado: (2021)

Outcome for Patients with Triple-Negative Breast Cancer Is Not Dependent on Race/Ethnicity
por: Chu, Quyen D., et al.
Publicado: (2012)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Development of an immune-related prognostic biomarker for triple-negative breast cancer
por: Zhang, Yan, et al.
Publicado: (2022)

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
por: Madera, Santiago, et al.
Publicado: (2022)

Halting Retrograde Transport Excludes ErbB-2 From the Nucleus Abrogating Tumor Growth in Triple Negative Breast Cancer
por: Madera, Santiago, et al.
Publicado: (2021)

Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort
por: Liu, Xiaoran, et al.
Publicado: (2017)

The risk of PD-L1 expression misclassification in triple-negative breast cancer
por: Ben Dori, Shani, et al.
Publicado: (2022)

Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue
por: Lee, Jieun, et al.
Publicado: (2017)

Identification of potential key genes and pathways predicting pathogenesis and prognosis for triple-negative breast cancer
por: Lv, Xuemei, et al.
Publicado: (2019)

Identification of candidate genes associated with triple negative breast cancer
por: Player, Audrey, et al.
Publicado: (2017)

Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms
por: Yeh, Shan-Ju, et al.
Publicado: (2021)

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population
por: Wang, Liye, et al.
Publicado: (2021)

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer
por: Yamashita, Nami, et al.
Publicado: (2021)

Medullary breast cancer is a predominantly triple-negative breast cancer – histopathological analysis and comparison with invasive ductal breast cancer
por: Budzik, Michał P., et al.
Publicado: (2019)

Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy
por: Ramadan, Wafaa S, et al.
Publicado: (2018)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

Identification of Cancer-Associated Fibroblast Subtype of Triple-Negative Breast Cancer
por: Wang, Maoli, et al.
Publicado: (2022)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
por: Houvenaeghel, G, et al.
Publicado: (2016)

Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer
por: Badowska-Kozakiewicz, Anna M., et al.
Publicado: (2018)

Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line
por: Dewi, Citra, et al.
Publicado: (2022)

ODP551 Halting ErbB-2 Isoforms Retrograde Transport to the Nucleus as a New Theragnostic Approach for Triple Negative Breast Cancer
por: Elizalde, Patricia Virginia, et al.
Publicado: (2022)

Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy
por: Talamantes, Sarah, et al.
Publicado: (2020)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6smlu5m22ijs796l1nicc63vpd